GLP-1 side effects: what the trials and labels report

GLP-1 medicines are effective but not side-effect free. This guide summarises what the clinical trials and prescribing labels report, so you know what is described in the evidence. It is general education, not advice for your situation — anything that concerns you belongs with the clinician who prescribed the medicine.

The common ones

Across the trials, the most frequently reported effects are gastrointestinal, and they tend to be worst when a dose is first increased:

• Nausea — the most common, usually easing over time.
• Vomiting, diarrhoea or constipation.
• Reduced appetite and early fullness (part of how they work).
• Injection-site reactions for the injected agents.

What labels and clinicians describe for tolerability

Prescribing information and clinical guidance commonly describe gradual dose escalation (titration) to reduce GI effects, and general eating patterns such as smaller meals. These are described in the labels and by prescribers — this guide is reporting them, not prescribing them or telling you to change anything yourself.

Less common but more serious

• Pancreatitis has been reported; severe, persistent abdominal pain is a reason to seek urgent care.
• Gallbladder problems can occur, particularly with rapid weight loss.
• Labels carry warnings relevant to specific groups (for example a thyroid-tumour boxed warning based on rodent data, and cautions in pregnancy).
• Dehydration from vomiting or diarrhoea can affect the kidneys.

This summarises published trial and label information; it is not medical advice and not personalised. Report side effects to your prescriber, and seek urgent care for severe or unusual symptoms.